The White House may have difficulty bolstering U.S. cyber defenses through an executive order unless there’s enough public support, according to former National Security Agency director Michael Hayden.
This time last year, the chairman and chief executive officer of Israel’s Teva Pharmaceutical Industries Ltd., the world’s biggest generic drugmaker, were foreigners. Miami billionaire Phillip Frost led the board and Jeremy Levin, a South African, was CEO. They were the first non- Israelis to hold those positions.
Huawei Technologies Co., China’s largest maker of telecommunications equipment, denied that it poses a security threat after the former director of the U.S. Central Intelligence Agency said it spies for China.
U.S. President Barack Obama’s call for more oversight and transparency in the National Security Agency’s surveillance programs shows that he wants to make Americans “more comfortable” with the agency’s operations, former NSA director Michael Hayden said.
Leaked information on U.S. government surveillance programs has “punished American business,” which has complied with court orders, said Michael Hayden, former director of the National Security Agency and the Central Intelligence Agency.
The disclosure of National Security Agency secrets by 29-year-old computer systems technician Edward Snowden is drawing new scrutiny of security processes and U.S. intelligence agencies’ reliance on contractors such as Snowden’s employer, Booz Allen Hamilton Holding Corp.
Sept. 30 (Bloomberg) -- Former CIA Director Michael Hayden talks about cyber security issues facing the U.S., Marion Blakey, president of the Aerospace Industries Association, discusses the need to avoid automatic cuts to U.S. defense spending. Bloomberg Government's Nela Richardson and Cady North report on financial regulation and the Volcker Rule. They speak with Peter Cook on Bloomberg Government's "Capitol Gains," which airs on Bloomberg Television. (Source: Bloomberg)
Teva Pharmaceutical Industries Ltd. will test its experimental multiple-sclerosis pill in combination therapies as the company mounts a response to oral competitors to its best-selling injection Copaxone.